We are international

Mesenchymal cell cytotherapy for multiple myeloma
Xin Li, PhD
Myeloma Institute for Research and Therapy
Winthrop P. Rockefeller Cancer Institute
University of Arkansas for Medical Sciences
Little Rock, AR, USA
Induction of myeloma bone disease is mediated through increased production of pro-osteoclastogenic and anti-osteoblastogenic factors in myelomatous bones, as well as due to potential abnormal properties of bone marrow mesenchymal stem cells (MSCs). Preliminary in vitro experiments by Dr. Li and colleagues showed that MSCs from normal bone marrow directly inhibit osteoclast formation and stimulate osteoblast differentiation, suggesting that these cells affect bone remodeling and myeloma cell growth via interaction with the host osteoclasts and osteoblasts. These findings have led to formulation of an overall hypothesis that, in contrast to patient MSCs, normal MSCs can help control myeloma directly and indirectly by preventing bone loss and stimulating bone formation. The research project will determine the direct effects of MSCs on osteoclasts and osteoblasts, shed light on molecular mechanism by which MSCs affect osteoclastogenesis and osteoblastogenesis. This can lead to new approaches to the treatment of myeloma bone disease.
 related articles
Bone marrow microenvironment and multiple myeloma chemotherapy optimization
Characterization and preclinical evaluation of NKT cells in multiple myeloma
Development of the antihelmintic flubendazole as a novel therapeutic agent for the treatment of multiple myeloma
MMSET and epigenetic control in t(4;14) myelomas
Novel anti-myeloma therapy by targeting molecular signaling regulated by galectin family proteins
Reolysin: a novel reovirus-based therapy for multiple myeloma